Intercure Ltd (INCR) Noticias

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility

InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility PR Newswire NEW YORK and...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million

Revenues during the first half of 2024 reached NIS 126 million, alongside an Adjusted EBITDA1of NIS 21 million...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InterCure Announces Expansion of its Strategic partnership with Cookies to Germany

InterCure expands its European footprint to launch Cookies Corners licensed pharmacies in Germany alongside differentiated online platforms with...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference

InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc), the leading medical cannabis company outside of North America, today announced that it...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]